Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

AstraZeneca
Baxter
Colorcon
Moodys
Medtronic
Express Scripts

Last Updated: October 15, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Poziotinib

See Plans and Pricing

« Back to Dashboard

Development status for investigational drug Poziotinib: Patents, clinical trial progress, indications

Poziotinib is an investigational drug.

There have been 15 clinical trials for Poziotinib. The most recent clinical trial was a Phase 2 trial, which was initiated on March 1st 2013.

The most common disease conditions in clinical trials are Breast Neoplasms, Lung Neoplasms, and Adenocarcinoma. The leading clinical trial sponsors are Spectrum Pharmaceuticals, Inc, Hanmi Pharmaceutical Company Limited, and National OncoVenture.

There are six US patents protecting this investigational drug and one hundred and eleven international patents.

Recent Clinical Trials for Poziotinib
TitleSponsorPhase
A Phase 2 Study of Poziotinib in Patients With NSCLC With EGFR or HER2 Exon 20 MutationHanmi Pharmaceutical Company LimitedPhase 2
A Mass Balance and Pharmacokinetics Study of 14C-Labeled Poziotinib in Cancer Patients Suitable for Treatment With PoziotinibSpectrum Pharmaceuticals, IncPhase 1
A Trial to Evaluate the Efficacy of Poziotinib, Pan HER Inhibitor in Recurrent/Metastatic Esophageal Cancer (R/M ESCC)Yonsei UniversityPhase 2

See all Poziotinib clinical trials

Clinical Trial Summary for Poziotinib

Top disease conditions for Poziotinib
Top clinical trial sponsors for Poziotinib

See all Poziotinib clinical trials

US Patents for Poziotinib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Poziotinib   See Pricing Amide derivative for inhibiting the growth of cancer cells Hanmi Holdings Co., Ltd. (Seoul, KR)   See Pricing
Poziotinib   See Pricing Method for EGFR directed combination treatment of non-small cell lung cancer Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE)   See Pricing
Poziotinib   See Pricing Method for preparing 1-(4-(4-(3,4-dichloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yloxy)pi- peridin-1-yl)-prop-2-en-1-one hydrochloride and intermediates used therein Hanmi Science Co., Ltd (Hwaseong-si, KR)   See Pricing
Poziotinib   See Pricing Method for preparing 1-(4-(4-(3,4-dichloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yloxy)pi- peridin-1-yi)prop-2-en-1-one Hanmi Pharm. Co., Ltd. (Gyeonggi-do, KR)   See Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Poziotinib

Drugname Country Document Number Estimated Expiration Related US Patent
Poziotinib Argentina 066876 2027-06-05   See Pricing
Poziotinib Argentina 110003 2027-06-05   See Pricing
Poziotinib Australia 2008260772 2027-06-05   See Pricing
Poziotinib Brazil PI0811069 2027-06-05   See Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Mallinckrodt
McKinsey
Boehringer Ingelheim
Merck
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.